Mar Iglesias
Overview
Explore the profile of Mar Iglesias including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
5029
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lop Gros J, Santiago Diaz P, Larrubia Loring M, Patriarca M, Lloveras B, Iglesias M
Appl Immunohistochem Mol Morphol
. 2025 Feb;
33(2):61-69.
PMID: 39894972
Claudin 18.2 is a transmembrane protein, part of the tight-junction complex, selectively expressed in gastric epithelium. It is showing promising results as a target in advanced gastric cancer in phase...
2.
Tejedor Vaquero S, Neuman H, Comerma L, Marcos-Fa X, Corral-Vazquez C, Uzzan M, et al.
J Exp Med
. 2024 Nov;
221(12).
PMID: 39560666
The human gut includes plasma cells (PCs) expressing immunoglobulin A1 (IgA1) or IgA2, two structurally distinct IgA subclasses with elusive regulation, function, and reactivity. We show here that intestinal IgA1+...
3.
Lopez J, Ielpo B, Iglesias M, Pinilla F, Sanchez-Velazquez P
Langenbecks Arch Surg
. 2024 Apr;
409(1):122.
PMID: 38607450
Purpose: Pancreatic ductal adenocarcinoma (PADC) still has nowadays a very impaired long-term survival. Most studies are focused on overall survival; however, local recurrence occurs about up to 50% of cases...
4.
Sole L, Lobo-Jarne T, Cabre-Romans J, Gonzalez A, Fernandez L, Marruecos L, et al.
Biochim Biophys Acta Mol Cell Res
. 2024 Jan;
1871(3):119658.
PMID: 38216091
Background: We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. From the set of genes differentially expressed in Chemotherapy Resistant Cells, we...
5.
Dal Cero M, Bencivenga M, Liu D, Sacco M, Alloggio M, Kerckhoffs K, et al.
Cancers (Basel)
. 2023 Nov;
15(21).
PMID: 37958365
Background: Conflicting results about the prognostic relevance of signet ring cell histology in gastric cancer have been reported. We aimed to perform a meta-analysis focusing on the clinicopathological features and...
6.
Badia-Ramentol J, Gimeno-Valiente F, Durendez E, Martinez-Ciarpaglini C, Linares J, Iglesias M, et al.
Cancer Treat Rev
. 2023 Oct;
121:102643.
PMID: 37871463
Adjuvant chemotherapy following surgical intervention remains the primary treatment option for patients with localized colorectal cancer (CRC). However, a significant proportion of patients will have an unfavorable outcome after current...
7.
Bencivenga M, Torroni L, Dal Cero M, Quinzii A, Zecchetto C, Merz V, et al.
J Pers Med
. 2023 Sep;
13(9).
PMID: 37763062
Poorly cohesive (PC) gastric cancer (GC) is extremely aggressive in progression, and there is an urgent need to identify the molecular pathways involved. We hypothesized the essential role of the...
8.
Pecharroman I, Sole L, Alvarez-Villanueva D, Lobo-Jarne T, Alonso-Maranon J, Bertran J, et al.
EMBO J
. 2023 Sep;
42(21):e114719.
PMID: 37737566
Activation of the IκB kinase (IKK) complex has recurrently been linked to colorectal cancer (CRC) initiation and progression. However, identification of downstream effectors other than NF-κB has remained elusive. Here,...
9.
Pumarega J, Gasull M, Koponen J, Campi L, Rantakokko P, Henriquez-Hernandez L, et al.
Environ Res
. 2023 Aug;
237(Pt 2):116965.
PMID: 37652221
Objective: To investigate the specific and combined effects of personal concentrations of some per- and polyfluoroalkyl substances (PFAS), other persistent organic pollutants (POPs), and chemical elements -measured in individuals' blood...
10.
Linares J, Varese M, Sallent-Aragay A, Mendez A, Palomo-Ponce S, Iglesias M, et al.
J Med Chem
. 2023 Feb;
66(5):3348-3355.
PMID: 36808993
The relative success of platinum (Pt)-based chemotherapy comes at the cost of severe adverse side effects and is associated with a high risk of pro-oncogenic activation in the tumor microenvironment....